Navigation Links
Vaxart Begins First Oral Vaccine Clinical Trial
Date:6/7/2011

SAN FRANCISCO, June 7, 2011 /PRNewswire/ -- Vaxart, Inc., a San Francisco biotechnology company developing oral-delivery vaccines, has begun dosing volunteers in a Phase I clinical trial. This is the first clinical study evaluating a vaccine that uses the company's novel oral-vaccine platform technology. The trial site is in the United States.

"This first trial in humans is important, because if safety is demonstrated with one vaccine, we can expect that later vaccines using the same Vaxart technology will also be safe," said Vaxart founder and CSO Sean Tucker, Ph.D.

Vaxart's first oral vaccine candidate is designed to protect against H5N1 Avian Influenza. The company also has a pipeline of additional vaccines in development, all based on its oral-delivery technology.

Vaxart also announced the issuance of U.S. patent no. 7,879,602, which provides broad protection for the company's oral-delivery technology. "This patent greatly increases the value of our portfolio because it covers all methods we know of for oral vaccination with a re-usable platform technology," said Vaxart CEO Michael Finney, Ph.D.

About Vaxart TechnologyVaxart leverages proprietary vaccine development and formulation approaches to quickly and efficiently produce oral-delivery vaccines. Central to the company's approach is the incorporation of a unique adjuvant, the vaccine component that enhances immune responses, in the vector that delivers the vaccine antigen. Vaxart's adjuvant works by binding to Toll-Like Receptor 3 to stimulate a potent immune response when the vaccine is taken orally.

Vaxart's technology also enables all of the company's vaccines to use the same vector, or delivery vehicle. Until now, each time an individual received a vector vaccine, a new vector needed to be used. This is because after receiving a vector vaccine, people develop antibodies to the vector itself, and these anti-vector antibodies reduce the effectiveness of later vaccin
'/>"/>

SOURCE Vaxart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
2. Vaxart Begins Animal Testing of H1N1 Flu Vaccine Candidate
3. GSK Begins Shipments of Fluarix(R) and FluLaval(R) to U.S. Customers for 2008-2009 Influenza Season
4. Cellectar, Inc. Begins GMP Production
5. South Africa Begins Introduction of PREVENAR into Childhood Immunization Program
6. Major Adult Vaccine Clinical Trial for Pneumonia Prevention Begins
7. The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
8. Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
9. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
10. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
11. SemBioSys begins phase I/II trial of insulin produced in plant seeds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 WriteResult, LLC – a ... been working with a team of researchers from Yale ... Community Farming Collaborative to provide electronic questionnaire data collection ... study, which started in May, aims to evaluate the ... weekly exposure to and participation in urban agriculture to ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 According ... Market by Service Type (Consulting, Integration, Deployment & ... by Deployment Model (Public, Private, Others (Hybrid & ... MarketsandMarkets, defines and segments the Cloud Professional Services ... and forecasting of revenues. It also identifies the ...
(Date:10/22/2014)... 22, 2014 Research and Markets  has ... by Material, by Application, Geography - Global Analysis and ... Organic electronics, also called as polymer ... science which deals with small conductive molecules and electrically ... molecules and polymers are carbon based, made using synthetic ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Convey ... that a team from Iowa State University won first ... contest. Using a Convey HC-2ex, the team’s solution achieved ... times faster than the second place finisher. , Experts ... embarked upon the month long challenge, using a variety ...
Breaking Biology Technology:myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... Oct. 17 Panacea Pharmaceuticals,Inc. announced today ... diagnostic test, is now available from Panacea ... that should facilitate the identification,of recurrence among ... a division of Panacea Pharmaceuticals, is certified ...
... SBS, CALGARY, Oct. 17 /PRNewswire-FirstCall/ - Botaneco, ... announced that it has reached an,agreement with AVAC ... the,development of Botaneco as an independent business. The ... period, beginning in the fourth,quarter of 2007, upon ...
... KYPH ) announced today that its stockholders approved ... MDT ) at a special,meeting of stockholders held ... Kyphon entered into a,definitive merger agreement with Medtronic, pursuant ... shares of Kyphon common stock for,$71.00 per share in ...
Cached Biology Technology:Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer 2Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer 3Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer 4Botaneco obtains $2.4 million in funding from AVAC 2Botaneco obtains $2.4 million in funding from AVAC 3Kyphon Stockholders Approve Merger with Medtronic 2
(Date:10/15/2014)... WASHINGTON, N.Y. , Oct. 15, 2014 /PRNewswire/ ... technology solutions for home and community-based care, today ... benefits of implementing Sandata,s Santrax® Electronic Visit Verification™ ... Care Services is a home health company founded ... Texas . The ...
(Date:10/15/2014)... bacterial pneumonia in female mice to an enzyme activated ... naturally more resistant to respiratory infections than males. Now, ... resistance to bacterial pneumonia in female mice is linked ... also show that this enzyme is ultimately activated by ... The team, lead by Professor Lester Kobzik at the ...
(Date:10/14/2014)... Research shows SIRT6—a protein known to inhibit the ... of skin cancers by turning on an enzyme that ... , Previously considered protective, SIRT6 is part of a ... genomic stability and prevent some of the genetic flaws ... can lead to cancer. This study, in the journal,s ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
... (ESA) will present its fifth annual Regional Policy Award ... during the Society,s upcoming conference in Portland, Oregon. The ... who has an outstanding record of informing political decision-making ... present this prestigious award to Ken Bierly for his ...
... (Boston) A recent study led by Boston University School ... plays a significant role in the regulation of high fat, ... which are published online in PLoS ONE , also ... type 2 diabetes. Katya Ravid, DSc/PhD, professor of ...
... Institution (WHOI) researchers have partnered with two companies ... WHOI: the Imaging FlowCytobot, an automated underwater microscope, ... light to provide wireless transmission of data, including ... WHOI biologists Robert Olson and Heidi Sosik, creators ...
Cached Biology News:Ken Bierly of the Oregon Watershed Enhancement Board to receive ESA Regional Policy Award 2Ken Bierly of the Oregon Watershed Enhancement Board to receive ESA Regional Policy Award 3BUSM study identifies receptor's role in regulating obesity, type 2 diabetes 2WHOI scientists/engineers partner with companies to market revolutionary new instruments 2WHOI scientists/engineers partner with companies to market revolutionary new instruments 3WHOI scientists/engineers partner with companies to market revolutionary new instruments 4
... have been many modifications to the original formulas ... solutions still play an important role in tissue,culture. ... pH and osmotic balance in the medium and ... inorganic ions, is as valuable today as when ...
Request Info...
... LXQ linear ion trap mass spectrometer enables ... laboratory., The LXQ linear ion trap mass ... proteomic applications, delivering the fast cycle time ... ion trap at an attractive price. ...
... Safe DNA gel stain was developed specifically for ... bromide for staining DNA in agarose or acrylamide ... mutagenic than ethidium bromide but SYBR Safe stain's ... bromide. SYBR Safe stain comes as a premixed ...
Biology Products: